Australia · Delayed Price · Currency is AUD Acrux Company Description
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.
The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream.
It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores.
The company was incorporated in 1998 and is based in West Melbourne, Australia.
| Country | Australia |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | John Warmbrunn |
Contact Details
Address: 103-113, Stanley Street West Melbourne, Victoria 3003 Australia | |
| Phone | 61 3 8379 0100 |
| Website | acrux.com.au |
Stock Details
| Ticker Symbol | ACR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ACR3 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Warmbrunn | MD, Chief Executive Officer and Director |
| Joanna Johnson B.E., BEc, ICAA | Chief Financial Officer and Company Secretary |
| Felicia Colagrande B.Sc., BSc (Hons), M.B.A., MBA | Product Development and Technical Affairs Director |
| Mark Hyman | Project and Technical Development Director |